Marina Biotech, Inc. (OTCMKTS:MRNA) reported that it has obtained a “notice of allowance” from the European Patent Office. It is related with the intent to grant the claims in its application which covers SMARTICLES® amphoteric liposomes formulated with an extensive range of unique sterol amphiphiles. Also, it obtained a “notice of allowance” of Canada Patent which covers methods for formulating a broad range of amphoteric liposomes. It covers SMARTICLES formulation which is currently in Phase 1 and Phase 2 clinical studies.

The significance

Marina Biotech stated that these patents cover both improved properties of its SMARTICLES formulation, like a modifiable charge and fusogenicity. The continued issuance and allowance of SMARTICLES-related patents extends the worldwide portfolio of nucleic acid delivery technology. Michael French, the CEO and President of Marina Biotech, said that the Canadian and European patents will be a major inclusion in the SMARTICLES global portfolio as the company continues to gather data that shows the clinical versatility of SMARTICLES.

The data

Most recently, SMARTICLES have shown cargo delivery outside the liver, as seen in part by Mirna Therapeutics’ report of SMARTICLES-mediated delivery. Expanding the reach of SMARTICLES shields one of Marina Biotech’s key delivery technologies and continues to facilitate company’s strategy to have most comprehensive and broadest nucleic acid drug discovery feature in the sector.

The funds

The company received a milestone payment from Marina Biotech, Inc. (OTCMKTS:MRNA), which considerably helped it to improve its cash position enabling it to move forward with the clinical plans. The focus is on preclinical and clinical plans and getting addition funds through near term licensing and collaboration deals.

In last trading session, the stock price of MRNA surged more than 10% to close the trading session at $0.505. The gains came at a share volume of 571,510 compared to a share volume of 48,040. The market cap stands at $12.95 million.

Previous articleLookSmart, Ltd. (NASDAQ:LOOK) Files Form 10-Q
Next articleInergetics Inc (OTCMKTS:NRTI) Files Form 10-Q
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.